Belumosudil Mesylate
Brand name: Rezurock
Rank #244 of 500 drugs by total cost
$52.3M
Total Cost
2,280
Total Claims
$52.3M
Total Cost
89
Prescribers
$23K
Cost per Claim
71
Beneficiaries
2,303
30-Day Fills
$587K
Avg Cost/Provider
26
Avg Claims/Provider
About Belumosudil Mesylate
Belumosudil Mesylate (sold as Rezurock) was prescribed 2,280 times by 89 Medicare Part D providers in 2023, costing the program $52.3M. At $23K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 241 | Buspirone Hcl (Buspirone Hcl) | $53.7M | 2,868,147 |
| 242 | Oxybutynin Chloride (Oxybutynin Chloride Er) | $53.4M | 1,872,901 |
| 243 | Raltegravir Potassium (Isentress) | $53.0M | 25,491 |
| 244 | Belumosudil Mesylate (Rezurock) | $52.3M | 2,280 |
| 245 | Pegloticase (Krystexxa) | $52.2M | 1,134 |
| 246 | Estrogens, Conjugated (Premarin) | $52.0M | 130,171 |
| 247 | Ranolazine (Ranolazine Er) | $51.6M | 381,631 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology